Durvalumab and Tremelimumab in Resectable HCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Durvalumab and Tremelimumab in Resectable HCC — Stella

Home/Hepatocellular Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Hepatocellular Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Canada

University Health Network, Toronto, Ontario

Italy

University of Milan, Milan

Spain

Clinica Universidad De Navarra, Pamplona

Key details

Phase

Safety & dosing

Sponsor

University Health Network, Toronto

Collaborators

Clinica Universidad de Navarra, Universidad de Navarra, University of Milan

Enrollment target

~28 participants

Started

October 2023

Primary completion

November 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.